🚀 VC round data is live in beta, check it out!
NextCure Valuation Multiples
Discover revenue and EBITDA valuation multiples for NextCure and similar public comparables like SyntekaBio, Intercure, Lipocine, Estrella Immunopharma and more.
NextCure Overview
About NextCure
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Founded
2015
HQ
Employees
43
Website
Sectors
Financials (LTM)
EV
$20M
NextCure Financials
NextCure reported last 12-month revenue of —.
In the same LTM period, NextCure generated — in gross profit and had net loss of ($53M).
Revenue (LTM)
NextCure P&L
In the most recent fiscal year, NextCure reported revenue of — and EBITDA of ($55M).
NextCure expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($55M) | XXX | XXX | XXX |
| Net Profit | ($53M) | XXX | ($56M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NextCure Stock Performance
NextCure has current market cap of $45M, and enterprise value of $20M.
Market Cap Evolution
NextCure's stock price is $12.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20M | $45M | 0.0% | XXX | XXX | XXX | $-15.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNextCure Valuation Multiples
NextCure trades at (0.4x) EV/EBITDA.
EV / Revenue (LTM)
NextCure Financial Valuation Multiples
As of March 18, 2026, NextCure has market cap of $45M and EV of $20M.
Equity research analysts estimate NextCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NextCure has a P/E ratio of (0.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45M | XXX | $45M | XXX | XXX | XXX |
| EV (current) | $20M | XXX | $20M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.4x) | XXX | XXX | XXX |
| EV/EBIT | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| P/E | (0.9x) | XXX | (0.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NextCure Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NextCure Margins & Growth Rates
NextCure's revenue in the last fiscal year grew by —.
NextCure's revenue per employee in the last FY averaged $0.0M.
NextCure Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NextCure Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Intercure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipocine | XXX | XXX | XXX | XXX | XXX | XXX |
| Estrella Immunopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NextCure M&A Activity
NextCure acquired XXX companies to date.
Last acquisition by NextCure was on XXXXXXXX, XXXXX. NextCure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NextCure
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNextCure Investment Activity
NextCure invested in XXX companies to date.
NextCure made its latest investment on XXXXXXXX, XXXXX. NextCure invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NextCure
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NextCure
| When was NextCure founded? | NextCure was founded in 2015. |
| Where is NextCure headquartered? | NextCure is headquartered in United States. |
| How many employees does NextCure have? | As of today, NextCure has over 43 employees. |
| Who is the CEO of NextCure? | NextCure's CEO is Michael S. Richman. |
| Is NextCure publicly listed? | Yes, NextCure is a public company listed on Nasdaq. |
| What is the stock symbol of NextCure? | NextCure trades under NXTC ticker. |
| When did NextCure go public? | NextCure went public in 2019. |
| Who are competitors of NextCure? | NextCure main competitors are SyntekaBio, Intercure, Lipocine, Estrella Immunopharma. |
| What is the current market cap of NextCure? | NextCure's current market cap is $45M. |
| Is NextCure profitable? | No, NextCure is not profitable. |
| What is the current net income of NextCure? | NextCure's last 12 months net income is ($53M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.